Also trades as: CSL.AX (ASX) · $vol 194M · CMXHF (OTC) · $vol 0M

$30.50

-0.44 (-1.42%)

Weekly Expected Move ±4.5%

$28 $29 $31 $32 $33

OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 58 · $118.1B mcap · 3.87B float · 0.0092% daily turnover · Short 37% of daily vol

Revenue

$15.8B +2.2% ▲

5Y CAGR: +9.0%

Gross Profit

$7.5B -5.4% ▼

5Y CAGR: +5.6%

Operating Income

$4.0B +36.2% ▲

5Y CAGR: +9.2%

Net Income

-$2.6B -186.3% ▼

EPS (Diluted)

$-1.34 -447.5% ▼

EBITDA

$5.1B -1.2% ▼

5Y CAGR: +6.9%

View Full Income Statement

Line Item	FY2022	FY2023	FY2024	FY2025	FY2026
Revenue	$10.5B	$13.2B	$14.8B	$15.4B	$15.8B
YoY Growth	+2.2%	+25.5%	+12.3%	+4.3%	+2.2%
Cost of Revenue	$4.8B	$6.5B	$7.1B	$7.5B	$8.2B
Gross Profit	$5.7B	$6.7B	$7.6B	$8.0B	$7.5B
Gross Margin	54.0%	50.9%	51.1%	51.5%	47.7%
R&D Expenses	$1.2B	$1.2B	$1.5B	$1.4B	$1.2B
SG&A Expenses	$1.6B	$2.5B	$2.4B	$2.6B	$2.1B
Operating Expenses	$3.3B	$3.9B	$4.8B	$5.0B	$3.5B
Operating Income	$2.9B	$2.9B	$3.8B	$3.0B	$4.0B
Operating Margin	27.9%	22.0%	25.8%	19.2%	25.6%
Interest Expense	$157M	$440M	$484M	$455M	$432M
Income Before Tax	$2.8B	$2.7B	$3.4B	$3.7B	-$4.1B
Tax Expense	$525M	$419M	$661M	$588M	-$1.1B
Net Income	$2.3B	$2.2B	$2.6B	$3.0B	-$2.6B
Net Margin	21.5%	16.7%	17.9%	19.5%	-16.4%
EPS (Diluted)	$2.40	$3.45	$2.73	$0.39	$-1.34
EBITDA	$3.5B	$3.9B	$4.7B	$5.1B	$5.1B
Shares Outstanding	940M	968M	970M	3.89B	1.93B

Line Item	FY2023 Q2	FY2023 Q4	FY2024 Q2	FY2024 Q4	FY2025 Q2	FY2025 Q4	FY2026 Q2	FY2026 Q4
Revenue	$7.3B	$5.9B	$8.4B	$6.7B	$8.2B	$7.3B	$8.3B	$7.4B
Cost of Revenue	$3.5B	$3.3B	$4.1B	$3.4B	$3.9B	$3.9B	$4.1B	$4.1B
Gross Profit	$3.8B	$2.6B	$4.3B	$3.4B	$4.3B	$3.4B	$4.2B	$3.3B
Gross Margin	51.6%	44.5%	51.3%	50.0%	52.1%	46.3%	50.7%	44.4%
R&D Expenses	$586M	$649M	$699M	$770M	$646M	$739M	$601M	$625M
SG&A Expenses	$1.0B	$1.2B	$904M	$1.3B	$1.2B	$1.2B	$1.0B	$1.1B
Operating Expenses	$1.6B	$1.8B	$1.7B	$2.2B	$1.8B	$2.0B	$1.6B	$1.9B
Operating Income	$2.1B	$818M	$2.7B	$1.2B	$2.8B	$1.4B	$2.6B	$1.4B
Operating Margin	29.4%	13.8%	32.1%	17.8%	33.6%	19.3%	31.3%	19.0%
Interest Expense	$209M	$235M	$265M	$450M	$221M	$216M	$213M	$218M
Income Before Tax	$2.0B	$690M	$2.5B	$996M	$2.5B	$1.2B	$381M	-$4.5B
Tax Expense	$329M	$95M	$479M	$202M	$484M	$108M	$94M	-$1.2B
Net Income	$1.7B	$595M	$2.0B	$741M	$2.0B	$1.0B	$402M	-$3.0B
Net Margin	22.9%	10.0%	23.7%	11.0%	24.4%	14.2%	4.8%	-40.2%
EPS (Diluted)	$1.73	$0.61	$2.05	$1.16	$2.07	—	$0.05	$-1.56
EBITDA	$2.6B	$1.4B	$3.2B	$1.6B	$3.2B	$2.0B	$3.1B	$2.0B
Shares Outstanding	967M	969M	970M	972M	972M	—	3.89B	1.92B

CSLLY OTC